INMED PHARMACEUTICALS INC. Business Acquisition, Pro Forma Net Income (Loss)
INMED PHARMACEUTICALS INC. (INM) reported Business Acquisition, Pro Forma Net Income (Loss) of -$19.26 million for the 12-month period ending 2023-06-30, per its 10-K filed 2023-09-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2023-09-29
- INMED PHARMACEUTICALS INC. business acquisition, pro forma net income (loss) for the quarter ending 2022-06-30 was -$8.79M.
- INMED PHARMACEUTICALS INC. business acquisition, pro forma net income (loss) for the quarter ending 2022-03-31 was -$3.39M.
- INMED PHARMACEUTICALS INC. business acquisition, pro forma net income (loss) for the quarter ending 2021-12-31 was -$4.22M.
- INMED PHARMACEUTICALS INC. business acquisition, pro forma net income (loss) for the quarter ending 2021-09-30 was -$2.85M.
- INMED PHARMACEUTICALS INC. business acquisition, pro forma net income (loss) for fiscal 2023 was -$19.26M.
- INMED PHARMACEUTICALS INC. business acquisition, pro forma net income (loss) for fiscal 2022 was -$19.26M.
- INMED PHARMACEUTICALS INC. business acquisition, pro forma net income (loss) for fiscal 2021 was -$10.71M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$19.26M 10-K · filed 2023-09-29 | |||
| 2022-06-30 | -$8.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | -$12.18M derived: sum of 2 quarters · filed 2022-09-23 | -$16.41M derived: sum of 3 quarters · filed 2022-09-23 | -$19.26M 10-K · filed 2022-09-23 |
| 2022-03-31 | -$3.39M 10-Q · filed 2022-05-13 | -$7.62M derived: sum of 2 quarters · filed 2022-05-13 | -$10.47M 10-Q · filed 2022-05-13 | -$12.52M derived: sum of 4 quarters · filed 2022-09-23 |
| 2021-12-31 | -$4.22M 10-Q · filed 2022-02-14 | -$7.10M 10-Q · filed 2022-02-14 | -$9.13M derived: sum of 3 quarters · filed 2022-09-23 | -$12.73M derived: sum of 4 quarters · filed 2022-09-23 |
| 2021-09-30 | -$2.85M derived: 10-K 12 month − 3 quarters · filed 2022-09-23 | -$4.90M derived: sum of 2 quarters · filed 2022-09-23 | -$8.51M derived: sum of 3 quarters · filed 2022-09-23 | -$11.42M derived: sum of 4 quarters · filed 2022-09-23 |
| 2021-06-30 | -$2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | -$5.65M derived: sum of 2 quarters · filed 2022-09-23 | -$8.57M derived: sum of 3 quarters · filed 2022-09-23 | -$10.71M 10-K · filed 2022-09-23 |
| 2021-03-31 | -$3.60M 10-Q · filed 2022-05-13 | -$6.52M derived: sum of 2 quarters · filed 2022-05-13 | -$8.65M 10-Q · filed 2022-05-13 | |
| 2020-12-31 | -$2.91M 10-Q · filed 2022-02-14 | -$5.05M 10-Q · filed 2022-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |